Company intelligence / Profile preview

Chloropept

Philadelphia, Pennsylvania, United Statesfacebook.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Chloropept is developing a novel animal feed containing peptides designed to treat bacterial infections in livestock while minimizing risks associated with antimicrobial resistance. The company leverages artificial intelligence and synthetic biology to identify new peptides that are effective against infectious bacteria. It was recognized as a runner-up at the iGEM 2024 Startup Showcase. No published clinical results yet.

Therapeutic areas: Infectious Diseases
Modalities: PeptidesAI-designed therapeutics
Industry: Veterinary

Partnerships

De la Fuente Lab, University of Pennsylvania (AI-driven peptide design collaboration)

Beyond the preview

Go deeper on Chloropept.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chloropept.

Explore the full profile